Interacciones de los nuevos ARV: etravirina, rilpivirina, darunavir, raltegravir, maraviroc

5. Key points When considering the PIs, significant interactions are unlikely between LPV/r or TMC114/r and the acid-reducing drug classes, so it is probable that these PIs can be co-administered with all classes of acid-reducing agents. Examination of the potential for drug interactions between the different PI-based regimens and the acid-reducing classes helps to clarify which drugs can, and cannot be co-administered. Significant interactions are likely between ATV or ATV/r and H2-blockers, and between atazanavir or atazanavir/r or IND and proton pomp inhibitors. ATV can be co-admninistered with H2-blockers if the drugs are administered separately, but the concomitant use of ATV or IDV and proton pomp inhibitors is contraindicated. Less significant interactions are likely between FPV/r or TPV/r and proton pomp inhibitors, though data are equivocal. It is possible that these PIs and proton pomp inhibitors can be co-administered. Significant interactions are unlikely between LPV/r or TMC114/r and the acid-reducing drug classes, so it is probable that these PIs can be co-administered with all classes of acid-reducing agents. The significance of interactions between SQV and H2-blockers or proton pomp inhibitors is currently unclear, although SQV absorption is not pH dependant. Reference Back D. Adapted from SPCs. Abbreviations ATV, atazanavir IDV, indinavir LPV, lopinavir PPI, proton pomp inhibitor r, low-dose ritonavir SQV, saquinavir TPV, tipranavir Key points When considering the PIs, significant interactions are unlikely between LPV/r or TMC114/r and the acid-reducing drug classes, so it is probable that these PIs can be co-administered with all classes of acid-reducing agents. Examination of the potential for drug interactions between the different PI-based regimens and the acid-reducing classes helps to clarify which drugs can, and cannot be co-administered. Significant interactions are likely between ATV or ATV/r and H2-blockers, and between atazanavir or atazanavir/r or IND and proton pomp inhibitors. ATV can be co-admninistered with H2-blockers if the drugs are administered separately, but the concomitant use of ATV or IDV and proton pomp inhibitors is contraindicated. Less significant interactions are likely between FPV/r or TPV/r and proton pomp inhibitors, though data are equivocal. It is possible that these PIs and proton pomp inhibitors can be co-administered. Significant interactions are unlikely between LPV/r or TMC114/r and the acid-reducing drug classes, so it is probable that these PIs can be co-administered with all classes of acid-reducing agents. The significance of interactions between SQV and H2-blockers or proton pomp inhibitors is currently unclear, although SQV absorption is not pH dependant. Reference Back D. Adapted from SPCs. Abbreviations ATV, atazanavir IDV, indinavir LPV, lopinavir PPI, proton pomp inhibitor r, low-dose ritonavir SQV, saquinavir TPV, tipranavir

14. Posible mecanismo: + UGT1A1 No se observaron efectos adversos graves.

33. Se metaboliza principalmente por glucuronidaci�n No presenta in vitro efecto inductor ni inhibidor enzim�tico. In vivo, RAL no modific� las concentraciones plasm�ticas de midazolam, conocido substrato del CYP3A4.

35. BENCHMRK-1 & -2 Combined Efficacy % of Patients With HIV RNA <50 copies/mL at Week 24� by Tipranavir (TPV) Use in OBT (Complete Week 24 Data) More than 100 pts were treated with a TPV-containing regimen and in those patients with active TPV the response rate was the same that those patients with 2 active drugs. Once again seems that PK changes in RAL have no effect in efficacy.More than 100 pts were treated with a TPV-containing regimen and in those patients with active TPV the response rate was the same that those patients with 2 active drugs. Once again seems that PK changes in RAL have no effect in efficacy.

37. http://www.interaccionesHIV.com http://www.hiv-druginteractions.org (Liverpool HIV Pharmacology Group) http://www.hivinsite.com/InSite.jsp?page=ar-00-02 (Universidad de California) http://www.hivmedicationguide.com (Canada) http://www.tthhivclinic.com/interact_tables.html (Toronto General Hospital) http://www.crha-health.ab.ca/clin/sac/druginte.htm (Southern Alberta Clinic).